Press release
In Vitro Diagnostics Market Size to Worth $157.63 Billion by 2030
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The global in vitro diagnostics (IVD) market is entering a phase of accelerated expansion, with industry valuation climbing from $101.05 billion in 2024 to $109.06 billion in 2025 and forecast to reach $157.63 billion by 2030-representing a compound annual growth rate (CAGR) of 7.6% during the 2025-2030 period.
Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=703 [https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=703&utm_source=abnewswire.com&utm_medium=referral&utm_campaign=paidpr]
What is driving this growth trajectory? Market momentum is anchored in the escalating prevalence of chronic and infectious diseases worldwide, the intensifying demand for rapid and precise diagnostic capabilities, and the strategic shift toward personalized medicine across healthcare systems. These forces are reshaping diagnostic workflows, investment priorities, and competitive dynamics across laboratories, hospitals, and point-of-care environments.
Strategic Market Insights: Where Value and Innovation Converge
Why does this matter for C-suite decision-makers? The IVD market represents a critical infrastructure layer supporting clinical outcomes, operational efficiency, and population health management. Strategic positioning within this market requires understanding where growth, technology, and end-user demand intersect.
North America maintains commanding market leadership, accounting for 38.7% of global IVD revenue in 2024, supported by advanced healthcare infrastructure, robust regulatory frameworks, and widespread adoption of molecular and immunoassay platforms. This regional dominance reflects sustained investment in precision diagnostics and digital health integration.
Reagents and kits constitute the market's revenue backbone, capturing 69.0% of global share in 2024. This segment's leadership stems from recurring consumable demand, high testing volumes, and essential deployment across all diagnostic platforms-from molecular workflows to clinical chemistry and immunoassays.
Who is positioned to capitalize on fastest-growing segments? Molecular diagnostics technology is projected to register the highest CAGR of 14.5% from 2025 to 2030, driven by advances in PCR, next-generation sequencing, and multiplexing capabilities. Point-of-care testing represents the fastest-growing site-of-testing segment, fueled by decentralization trends and demand for near-patient diagnostic solutions.
Technology Disruption and Clinical Transformation
How are technological advances reshaping the market? Innovations in chemiluminescence assays, digital diagnostic platforms, and automated high-throughput analyzers are enhancing clinical efficiency and accelerating decision-making timelines. The integration of artificial intelligence, data analytics, and connectivity into diagnostic systems is fundamentally transforming laboratory operations and test result interpretation.
Blood, serum, and plasma specimens continue to dominate specimen types due to broad clinical applicability and compatibility with diverse diagnostic modalities. Infectious disease applications accounted for the largest application share in 2024, reflecting persistent global demand for pathogen screening, outbreak response, and chronic infection monitoring.
Hospitals and clinics remain the largest end-user segment, driven by high patient volumes, comprehensive testing requirements, and integration of advanced molecular platforms and immunoassay analyzers within clinical workflows.
Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=703 [https://www.marketsandmarkets.com/requestsampleNew.asp?id=703&utm_source=abnewswire.com&utm_medium=referral&utm_campaign=paidpr]
Competitive Landscape: Market Leaders and Emerging Innovators
Who are the dominant players shaping market evolution? F. Hoffmann-La Roche, Danaher, and Abbott have been identified as Star players within the global IVD competitive matrix, distinguished by extensive diagnostic portfolios, substantial market presence, and sustained leadership across high-value testing segments including molecular diagnostics, immunoassays, and clinical chemistry.
Among small and medium enterprises, Devyser and Surmodics have carved out strong positions in specialized diagnostic niches, demonstrating innovation potential and strategic agility within targeted market segments.
Market Dynamics: Navigating Opportunities and Challenges
What opportunities are emerging for strategic investors? Improvements in immunoassay diagnostic technologies-including high-sensitivity platforms, automation capabilities, and multiplexing functions-are creating substantial growth avenues. Developing markets present significant expansion opportunities as healthcare infrastructure modernizes and early disease detection awareness increases.
When do regulatory and operational barriers pose constraints? Stringent regulatory requirements, particularly IVDR compliance in Europe and FDA standards in the United States, extend product development timelines and increase compliance costs. Operational challenges including skilled labor shortages, instrument maintenance expenses, and supply chain vulnerabilities continue to affect deployment efficiency and testing consistency.
Data privacy and cybersecurity risks represent emerging challenges as diagnostic systems become increasingly connected and data-intensive.
Industry Use Cases: Validated Commercial Applications
Leading diagnostic platforms demonstrate measurable performance advantages across clinical settings. Roche's cobas molecular systems deliver high-throughput viral load testing with superior analytical accuracy and automated workflows for centralized laboratories. Abbott's Alinity m analyzers provide rapid molecular detection with minimal manual intervention for infectious disease diagnostics. Cepheid's GeneXpert systems enable decentralized, cartridge-based molecular testing suitable for point-of-care and low-resource environments.
Siemens Healthineers' Atellica CI Analyzer integrates clinical chemistry and immunoassay testing to improve operational efficiency and turnaround times in hospital laboratories. Illumina's NextSeq 550Dx instrument supports high-throughput next-generation sequencing for oncology and genetic testing applications, advancing precision medicine capabilities.
Market Ecosystem and Value Chain Integration
Where does collaboration drive market advancement? The IVD ecosystem comprises specialized suppliers including Abacus ALS, diagnostic manufacturers, and major healthcare institutions such as Cleveland Clinic, Johns Hopkins Medicine, and Unilabs. Suppliers provide critical reagents, consumables, and instrument components. Healthcare institutions drive demand for accuracy, speed, and high-throughput capabilities to support clinical decision-making and population health initiatives.
Sustained collaboration across suppliers, manufacturers, and diagnostic service providers remains essential to ensure innovation velocity, regulatory compliance, and improved clinical outcomes.
Regional Market Dynamics
North America's market leadership through 2030 is reinforced by advanced healthcare infrastructure, high adoption rates of molecular and immunoassay technologies, and substantial investments in precision medicine and digital diagnostic platforms. Growing demand for infectious disease testing, chronic disease monitoring, and rapid diagnostic workflows further solidifies the region's dominant position.
Recent Strategic Developments
February 2025: F. Hoffmann-La Roche Ltd introduced a novel class of next-generation sequencing powered by proprietary Sequencing by Expansion (SBX) technology, targeting enhanced accuracy, efficiency, and scalability.
November 2024: F. Hoffmann-La Roche Ltd entered a definitive merger agreement to acquire Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company specializing in donor-derived CAR-T cell therapies, strengthening its cell and gene therapy portfolio.
July 2024: Beckman Coulter, Inc. and Fujirebio announced collaboration to identify novel blood-based biomarkers and advance existing biomarker development for tau pathology in Alzheimer's disease.
Strategic Implications for Decision-Makers
The in vitro diagnostics market represents a convergence of clinical necessity, technological innovation, and commercial opportunity. Organizations positioned to capitalize on molecular diagnostics growth, point-of-care testing expansion, and immunoassay technology improvements will secure competitive advantages in an increasingly precision-driven healthcare landscape.
Strategic investment priorities should emphasize automation capabilities, regulatory compliance infrastructure, data security frameworks, and partnership ecosystems that accelerate market access and clinical validation.
Market Scope and Methodology
This analysis encompasses comprehensive evaluation across product categories (reagents & kits, instruments, data management software), technology platforms (immunoassays, clinical chemistry, molecular diagnostics, glucose monitoring, hematology, microbiology, coagulation, blood gas analyzers, urinalysis, chromatography), specimen types, testing sites, clinical applications, and end-user segments across North America, Europe, Asia Pacific, Latin America, Middle East & Africa, and GCC countries.
The forecast period extends from 2025 to 2030, with 2024 as the base year. Market sizing includes value metrics (USD million/billion) and volume considerations, supported by secondary research, expert interviews, and comprehensive competitive analysis.
Key Market Participants
Danaher (US), F. Hoffmann-La Roche Ltd (Switzerland), Abbott (US), Siemens Healthineers AG (Germany), Thermo Fisher Scientific, Inc. (US), Illumina, Inc. (US), Hologic, Inc. (US), Bio-Rad Laboratories, Inc. (US), bioMerieux (France), Sysmex Corporation (Japan), Revvity Inc (US), Becton, Dickinson and Company (US), Agilent Technologies, Inc. (US), Qiagen (Netherlands), DiaSorin S.p.A. (Italy), Grifols, S.A. (Spain), Werfen (Spain), QuidelOrtho Corporation (US).
Media Contact
Company Name: MarketsandMarkets Trademark Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=in-vitro-diagnostics-market-size-to-worth-15763-billion-by-2030]
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/ivd-in-vitro-diagnostics-market-703.html
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release In Vitro Diagnostics Market Size to Worth $157.63 Billion by 2030 here
News-ID: 4369817 • Views: …
More Releases from ABNewswire
Revenue Cycle Management (RCM) Market Size to Worth USD 117.50 Billion by 2030
Revenue Cycle Management (RCM) Market by Offering [Product (Front, Mid, Back-end Solutions), Outsourcing Service], Enterprise Size [Large, SMEs], Technology [AI, Non-AI], End User [Inpatient, Outpatient, Payer, Pharmacy] & Region - Global Forecast to 2030
The global revenue cycle management (RCM) market is experiencing unprecedented expansion, driven by fundamental shifts in healthcare economics and the strategic imperative for operational excellence. Valued at $58.27 billion in 2024 and reaching $65.49 billion in 2025,…
Chromatography Columns Market Size to Worth USD 4.22 Billion by 2031
Chromatography Columns Market by Column Type (Ion Exchange, Size Exclusion, Reverse and Normal Phases, HPLC, Affinity, Chiral), Capacity (1-100 ml, 100-1000 ml, >1 liter), End User (Pharma & Biotech, CRO, CDMO) Global Forecast to 2031
The global chromatography columns market is entering a period of sustained expansion, with valuation rising from $2.77 billion in 2025 to a projected $4.22 billion by 2031, reflecting a compound annual growth rate (CAGR) of 7.3%.…
ENDRA Life Sciences (NASDAQ: NDRA) Gaining Attention as HYPE Token Surges See Wh …
As markets increasingly blur the line between traditional finance and digital assets, ENDRA Life Sciences (NASDAQ: NDRA) is emerging as a unique small-cap story positioned at the intersection of health-tech innovation and next-generation treasury strategy. Recent developments in the digital asset markets-particularly the sharp rise in the HYPE token-are drawing renewed attention to companies that have strategically aligned their balance sheets with this convergence.
HYPE Token Momentum Signals a Broader Market…
Stocks Under $1: TOON, HCTI, XPON, PRSO, GCTS - Watch Now
As investors continue to search for high-upside opportunities in the microcap market, stocks trading under $1 remain firmly on the radar. While these names carry higher volatility and risk, they also tend to attract disproportionate attention during periods of market rotation, speculative momentum, and renewed retail participation.
The following under-$1 stocks span entertainment, healthcare technology, energy storage, and next-generation semiconductors-sectors aligned with long-term structural growth trends. Together, they form a microcap…
More Releases for IVD
Transformative Trends Impacting the Cancer In Vitro Diagnostics (IVD) Market Lan …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Cancer In Vitro Diagnostics (IVD) Market Size By 2025?
The market size for cancer in vitro diagnostics (IVD) has seen significant growth in the past few years. The market value, which is expected to be $13.36 billion in 2024, is projected to increase to $14.32…
In Vitro Diagnostics (IVD) Market
With the watchful use of established and advanced tools such as SWOT analysis and Porter's Five Forces Analysis, this market report has been structured. While preparing this In Vitro Diagnostics (IVD) Market research report, few of the attributes that have been adopted include highest level of spirit, practical solutions, committed research and analysis, innovation, integrated approaches, and most up-to-date technology.
Every possible effort has been taken while researching and analysing…
Companion Animal IVD Market - Guiding the Path to Optimal Health: Empowering Vet …
Newark, New Castle, USA - new report, titled Companion Animal IVD Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Companion Animal IVD market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Companion Animal IVD market. The report offers an overview of…
IVD Market 2021 | Detailed Report
The IVD market research report delivers accurate data and innovative corporate analysis, helping organizations of all sizes make appropriate decisions. The IVD report also incorporates the current and future global market outlook in the emerging and developed markets. Moreover, the report also investigates regions/countries expected to witness the fastest growth rates during the forecast period.
The IVD research report also provides insights of different regions that are contributing market growth.…
Liquid Biopsy IVD Market 2021 | Detailed Report
According to Market Study Report, Liquid Biopsy IVD Market provides a comprehensive analysis of the Liquid Biopsy IVD Market segments, including their dynamics, size, growth, regulatory requirements, competitive landscape, and emerging opportunities of global industry. An exclusive data offered in this report is collected by research and industry experts team.
Get Free Sample PDF (including full TOC, Tables and Figures) of Liquid Biopsy IVD Market @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=4623688
The report provides a…
Asia IVD Market
According to a new report published by Allied Market Research, the Asia Pacific In-vitro diagnostics market was valued at $12.9 billion in 2015, and is expected to reach $19.0 billion registering a CAGR of 5.6% during 2016 to 2022. The report offers a detailed analysis of the key segments, top investment pockets, changing dynamics, market size & estimations, and competitive scenario.
Download Free Sample Report @ https://www.alliedmarketresearch.com/request-sample/1256
The Asia-Pacific IVD market is…
